MiSight 1 Day Safety Post-Approval Study
Launched by COOPERVISION, INC. · Mar 9, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The MiSight 1 Day Safety Post-Approval Study is looking to confirm the safety of daily disposable soft contact lenses for children aged 8 to 12 who have myopia, which is a condition where distant objects appear blurry. If your child is between 8 and 12 years old, has a specific level of vision correction need, and is interested in wearing contact lenses for about 10 hours a day, they may be eligible to participate. It’s important that they have glasses they can wear as well.
Participants in this study will wear the MiSight contact lenses while researchers monitor their eye health and comfort. They need to be free from serious eye conditions and infections to ensure safety during the study. The parents or guardians will need to give permission for their child to take part and share some health information. This study is currently recruiting participants, and it’s a great opportunity for children who want to try contact lenses in a safe, supervised environment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Be between 8 and 12 years of age inclusive at the time of enrollment.
- • 2. Manifest Refraction - Spherical Equivalent Refractive Error (SERE) at baseline between -0.50 D and -7.00 D inclusive (at the corneal plane).
- • 3. Best-corrected visual acuity by manifest refraction of at least 20/25 bilaterally
- • 4. Free of ocular disease or abnormalities (including any corneal scar)
- • 5. The parent/guardian must be capable of comprehending the nature of the study and consent to the use and release of their child's de-identified health care encounter data to be used for purposes of this study. Assent will be obtained from the child in a manner specified by the IRB.
- • 6. Parent/Guardian must sign the Release of Medical Records associated with the outcomes of interest identified from claims data.
- • 7. Interested in wearing contact lenses for approximately 10 hours per day and 6 days per week.
- • 8. Possesses, or obtains prior to dispensing, wearable and visually functional (20/40 or better) eyeglasses.
- Exclusion Criteria:
- • 1. Acute and subacute inflammation or infection of the anterior chamber of the eye.
- • 2. Any eye disease, injury, or abnormality that affects the cornea, conjunctiva, or eyelids.
- • 3. Severe insufficiency of lacrimal secretion (dry eyes).
- • 4. Corneal hypoesthesia (reduced corneal sensitivity), if not aphakic.
- • 5. Any systemic disease that may affect the eye or be exaggerated by wearing contact lenses.
- • 6. Allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated by wearing contact lenses or use of contact lens solutions.
- • 7. Any active corneal infection (bacterial, fungal, or viral).
- • 8. If eyes are red or irritated.
- • 9. The patient is unable to follow lens handling and wear regimen or unable to obtain assistance to do so.
- • 10. In addition to the labeling contraindications, children who are under medication that would interfere with contact lens wear, or who are using any pharmaceuticals for control of myopia will not be included in the study.
About Coopervision, Inc.
CooperVision, Inc. is a global leader in the contact lens industry, dedicated to advancing the science of vision care through innovative products and clinical research. With a commitment to enhancing the quality of life for millions of wearers worldwide, the company specializes in developing a diverse range of contact lenses, including those for myopia control, astigmatism, and presbyopia. CooperVision actively engages in clinical trials to ensure the safety, efficacy, and comfort of its products, while also contributing to the broader understanding of eye health and vision correction. By fostering partnerships with healthcare professionals and researchers, CooperVision aims to drive advancements in vision care and provide exceptional solutions that meet the evolving needs of eye care practitioners and their patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milford, Connecticut, United States
Glenview, Illinois, United States
Bellaire, Texas, United States
Danville, California, United States
Fremont, California, United States
Irvine, California, United States
Centennial, Colorado, United States
Saint Johns, Florida, United States
Chicago, Illinois, United States
Morristown, New Jersey, United States
Apex, North Carolina, United States
Chagrin Falls, Ohio, United States
State College, Pennsylvania, United States
Redmond, Washington, United States
Gilbert, Arizona, United States
San Jose, California, United States
Oviedo, Florida, United States
Chicago, Illinois, United States
Carmel, Indiana, United States
Rockville, Maryland, United States
Wellesley, Massachusetts, United States
California, Missouri, United States
Des Peres, Missouri, United States
Bronx, New York, United States
Frisco, Texas, United States
Pleasant Grove, Utah, United States
Sandy, Utah, United States
Morgantown, West Virginia, United States
Beaumont, Texas, United States
San Jose, California, United States
Miami, Florida, United States
Cupertino, California, United States
Dublin, California, United States
Milpitas, California, United States
Oakland, California, United States
Lake Worth, Florida, United States
Pickerington, Ohio, United States
Plano, Texas, United States
Salt Lake City, Utah, United States
Williamsburg, Virginia, United States
San Antonio, Texas, United States
Centerton, Arkansas, United States
Sarasota, Florida, United States
Weston, Florida, United States
Darien, Illinois, United States
Cary, North Carolina, United States
Berkeley, California, United States
Cupertino, California, United States
St. Johns, Florida, United States
Bronx, New York, United States
Corpus Christi, Texas, United States
Markham, Ontario, Canada
Oakville, Ontario, Canada
Patients applied
Trial Officials
William Gleason, OD
Principal Investigator
Foresight Regulatory Strategies
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials